Recent News

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC

ASTRO 2020: Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC

Timing of Brain Radiotherapy for NSCLC With Brain Metastasis

ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer

Equivalence Study of Bevacizumab Biosimilar in Metastatic Nonsquamous NSCLC

ASTRO 2020: Cardiac Events With Photon Versus Proton Radiotherapy for Lung Cancer

Lung Cancer and Severity of COVID-19: Experience From MSK

Osimertinib Receives Priority Review for EGFR-Mutant NSCLC

Early Clinical Data on Sotorasib in Advanced NSCLC

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153

ESMO 2020: Does Immune Oncology Increase the Risk of SARS-CoV2–Related Mortality in NSCLC?

ESMO 2020: Pembrolizumab Versus Docetaxel in Subgroup of Patients With NSCLC

ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer

ESMO 2020: First-Line Pembrolizumab, Chemotherapy, and Lenvatinib in Metastatic NSCLC

Study Supports Use of RET Inhibitor in RET Fusion–Positive Lung Cancer

ESMO 2020: CNS Recurrence Patterns With Osimertinib in Treatment of NSCLC

ESMO 2020: Is Neoadjuvant Atezolizumab Safe in Patients With Resectable NSCLC?

ESMO 2020: Combining Ipilimumab With PD-1 Blockade in Advanced Lung Cancer

ESMO 2020: Lorlatinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC

ESMO 2020: Is Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes of Benefit?

COVID-19 and Lung Cancer: Skin Manifestations With Immunotherapy

Are ‘Light’ Smokers at Increased Risk of Death From Lung Cancer?

FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer

Pralsetinib Approved by FDA for Metastatic RET Fusion–Positive NSCLC

Survival Outcomes in Lung Cancer in the United Kingdom During the COVID-19 Pandemic

COVID-19 and Thoracic Cancer: First Results From TERAVOLT

Liquid Biopsy Companion Diagnostic Test Approved for Metastatic NSCLC

Lung Cancer and COVID-19: Global Experts Offer Treatment Guidance

Does Nicotine Promote Brain Metastasis of Lung Cancer?

FDA Grants Priority Review for New Durvalumab Dosing Regimen in NSCLC

AACR COVID-19: SRMS Expression in Patients With Lung Cancer

WCLC 2020: Ensartinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC

AACR COVID-19: Changes in Lung Cancer Management

WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC

Phase I Trial of Combined MEK and EGFR Inhibition in NSCLC

COVID-19 and Lung Cancer: Proactive Measures for Screening Patients

Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer

ctDNA Clearance and Savolitinib Plus Osimertinib in MET-Amplified Lung Cancer

Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC

AACR COVID-19: Study Finds Age-Related Differences for Survival

Glucose Transporter Inhibition: Potential Treatment of Certain Lung Cancers

AACR COVID-19: Continuity of Care in Lung Cancer

Adding Platinum Doublet to Immunotherapy Combination in Advanced Lung Cancer

The Gut Microbiome's Response to Immunotherapy for Lung Cancer

Mobile Program Brings Lung Cancer Screening to Patients

Icotinib Dosage May Affect Outcomes in Patients With NSCLC and Genetic Mutation

AACR II: Environmental Factors and Lung Cancer Risk

Screening for Lung Cancer: Draft Recommendation From USPSTF

AACR II: Early-Phase Study of Ensartinib in ALK-Positive NSCLC

Multidisciplinary Care Coordination for Patients With NSCLC

AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer

Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC

HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer

AACR II: Potential Link Between Lung Cancer Risk and Sleep Patterns

ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC

ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC

ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC

Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma

ASCO20: Dual EGFR Tyrosine Kinase Inhibitor Therapy for EGFR-Mutated NSCLC

Frequency of Cardiovascular Events in Patients With Lung Cancer

ASCO20: MET Inhibitor for Lung Cancer With MET Exon 14 Skipping Mutation

Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Lung Cancer?

ASCO20: Adding Local Stereotactic Radiotherapy to TKI in Oligometastatic Lung Cancer

COVID-19 and Lung Cancer: Should ALK/ROS1 Inhibitor Therapy Be Continued?

ASCO20: Immunotherapy Combination Plus Chemotherapy for Advanced NSCLC

Ramucirumab Plus Erlotinib Approved by FDA in Metastatic NSCLC